###begin article-title 0
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 18 20 18 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 357 358 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 362 364 346 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 365 369 349 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 618 622 602 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 712 713 692 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 717 719 697 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 791 792 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 796 798 776 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 901 909 877 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 987 988 963 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 992 994 968 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1141 1145 1113 1117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1307 1311 1275 1279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1384 1388 1352 1356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 218 221 <span type="species:ncbi:31658">CFA</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 444 447 <span type="species:ncbi:31658">CFA</span>
###xml 840 844 <span type="species:ncbi:10090">mice</span>
###xml 951 954 <span type="species:ncbi:31658">CFA</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1286 1290 <span type="species:ncbi:10090">mice</span>
Mice with a deficiency in IFN-gamma or IFN-gamma receptor (IFN-gammaR) are more susceptible to collagen-induced arthritis (CIA), an experimental autoimmune disease that relies on the use of complete Freund's adjuvant (CFA). Here we report that the heightened susceptibility of IFN-gammaR knock-out (KO) mice is associated with a functional impairment of CD4+CD25+ Treg cells. Treatment of wild-type mice with depleting anti-CD25 antibody after CFA-assisted immunisation with collagen type II (CII) significantly accelerated the onset of arthritis and increased the severity of CIA. This is an indication of a role of Treg cells in the effector phase of CIA. IFN-gammaR deficiency did not affect the number of CD4+CD25+ T cells in the central and peripheral lymphoid tissues. In addition, CD4+CD25+ T cells isolated from naive IFN-gammaR KO mice had a normal potential to suppress T cell proliferation in vitro. However, after immunisation with CII in CFA, the suppressive activity of CD4+CD25+ T cells became significantly more impaired in IFN-gammaR-deficient mice. Moreover, expression of the mRNA for Foxp3, a highly specific marker for Treg cells, was lower. We further demonstrated that the effect of endogenous IFN-gamma, which accounts for more suppressive activity in wild-type mice, concerns both Treg cells and accessory cells. Our results demonstrate that the decrease in Treg cell activity in CIA is counter-regulated by endogenous IFN-gamma.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 951 952 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 976 978 976 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1062 1063 1062 1063 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1067 1069 1067 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1095 1097 1095 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nu</italic>
###xml 1098 1101 1098 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nu </italic>
###xml 1185 1186 1185 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1211 1212 1211 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1216 1218 1216 1218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1267 1268 1267 1268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1272 1274 1272 1274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1281 1282 1281 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1286 1288 1286 1288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1346 1350 1346 1350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 1355 1359 1355 1359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1369 1370 1369 1370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1374 1376 1374 1376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1377 1381 1377 1381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1528 1529 1528 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1530 1531 1530 1531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1541 1542 1541 1542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1546 1548 1546 1548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1549 1553 1549 1553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1607 1609 1607 1609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1038 1042 <span type="species:ncbi:10090">mice</span>
###xml 1101 1105 <span type="species:ncbi:10090">mice</span>
The adaptive immune system uses various potent effector mechanisms for the elimination of foreign pathogens. Because these mechanisms are potentially damaging to the host, an essential feature of the immune system is its ability to distinguish self from non-self antigens and to develop tolerance to the former. With regard to T cell tolerance, the immune system has evolved several strategies. Most autoreactive T cells are eliminated during (primary) maturation in the thymus, a process described as negative selection, resulting in central T cell tolerance. Autoreactive T cells that escape negative selection will nevertheless be prevented from being activated as they are confronted with auto-antigen in the periphery. Several mechanisms have been proposed to account for this peripheral tolerance. One of those is suppression by a subset of T cells that express both CD4 and CD25. Evidence for the important role of these cells is overwhelming [1]. For example, when CD4+ T cells isolated from peripheral lymphoid tissues of normal mice are depleted of CD4+CD25+ T cells and injected into nu/nu mice, the recipients develop a high incidence of organ-specific autoimmune disease [2]. Co-transfer of the CD4+CD25+ population prevents the induction of disease. CD4+CD25- and CD4+CD25+ T cells are therefore often designated as, respectively, Teff and Treg cells. CD4+CD25+ Treg cells are generated in the thymus. Their development is directed by relatively high-avidity interactions between the TCR and self-peptide ligands [3-5]. The CD4+CD25+ Treg cell population constitutes 5 to 10% of the mature CD4+ cell population in the adult thymus and the peripheral lymphoid tissue and blood.
###end p 4
###begin p 5
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 18 20 18 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 21 25 21 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 203 205 203 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 380 384 380 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 544 545 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 546 548 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 582 583 576 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 660 662 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
In vitro, CD4+CD25+ Treg cells inhibit polyclonal T cell activation [6,7]. The suppression is mediated by a cytokine-independent, cell contact-dependent mechanism that requires activation of the CD4+CD25+ cells via the TCR with specific antigen [8]. However, once stimulated, they are competent to suppress in an antigen-independent manner. Although the exact mechanism by which Treg cells exert their regulatory function is still unknown, there are indications that interaction of transforming growth factor-beta (TGF-beta) with its receptor [9-11], inhibition of IL-2 production [6] or downregulation of co-stimulatory molecules on antigen-presenting cells [12] could be involved.
###end p 5
###begin p 6
###xml 1 5 1 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 125 133 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 201 203 201 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 227 229 227 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nu/nu </italic>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 349 353 349 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 510 511 510 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 514 516 514 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 669 670 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 674 676 674 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 677 681 677 681 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 580 595 <span type="species:ncbi:10090">transgenic mice</span>
Treg cells have proved to be important in various animal models of autoimmune diseases. Administration of anti-CD25 antibody in vivo induces organ-localised autoimmune diseases [13]. Inoculation of CD4+ T cells depleted of CD25+ cells in nu/nu mice results in autoimmune diseases such as gastritis, thyroiditis and insulitis [2]. Thus, transfer of Treg cells prevents autoimmune gastritis after neonatal thymectomy, and inhibits gastritis induced by H/K ATPase-reactive effector T cells [14]. MBP-specific CD25+CD4+ T cells prevent spontaneous autoimmune encephalomyelitis in TCR-transgenic mice deficient in the recombination activating gene RAG-1 [15]. Similarly, CD4+CD25+ Treg cells suppress central nervous system inflammation during active experimental autoimmune encephalomyelitis [16].
###end p 6
###begin p 7
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 408 410 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 411 413 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 525 527 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 528 530 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
Collagen-induced arthritis (CIA) is a well-described animal model for rheumatoid arthritis. The disease is induced in genetically susceptible DBA/1 mice by immunisation with collagen type II (CII), and both T cell and B cell autoimmune responses are required for its development [17-19]. IFN-gamma receptor knock-out (IFN-gammaR KO) mice have been found to suffer an accelerated and more severe form of CIA [20-23]. Moreover, knocking-out of the IFN-gamma gene makes genetically resistant strains of mice susceptible to CIA [24,25]. These data indicate that deletion of the IFN-gamma response somehow disrupts an endogenous protective mechanism against CIA.
###end p 7
###begin p 8
###xml 23 25 23 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 66 70 66 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 171 175 171 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 256 260 256 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 618 619 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 623 625 615 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 626 630 618 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 677 681 669 673 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 799 803 787 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 883 892 867 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 912 913 896 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 917 919 901 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 920 924 904 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
###xml 826 830 <span type="species:ncbi:10090">mice</span>
Morgan and colleagues [26] have recently demonstrated that CD25+ Treg cells are important in the pathogenesis of CIA. In the present study we confirmed the importance of Treg cells in the pathogenesis of CIA by rendering wild-type DBA/1 mice deficient in Treg cells by depleting anti-CD25 antibodies. Anti-CD25-treated mice developed a significantly more severe arthritis, comparable to the disease course in IFN-gammaR KO mice. Thus, we proposed that the higher susceptibility of IFN-gammaR KO DBA/1 mice to CIA might be ascribed to defects in the production (differentiation and homeostasis) or function of these CD4+CD25+ Treg cells. We therefore determined the numbers of Treg cells in central and peripheral lymphoid organs of IFN-gammaR KO and wild-type mice. We further investigated whether Treg cells of IFN-gammaR KO mice have defects in the ability to suppress TCR-induced in vitro proliferation of CD4+CD25- Teff cells.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and experimental conditions
###end title 10
###begin p 11
###xml 204 206 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 433 435 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 330 334 <span type="species:ncbi:10090">mice</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 656 660 <span type="species:ncbi:10090">mice</span>
The generation and the basic characteristics of the mutant mouse strain (129/Sv/Ev) with a disruption in the gene coding for the alpha-chain of the IFN-gamma receptor (IFN-gammaR KO) have been described [27]. These IFN-gammaR KO mice were backcrossed with DBA/1 wild-type mice for 10 generations to obtain the DBA/1 IFN-gammaR KO mice used in the present study. The homozygous IFN-gammaR KO mice were identified by PCR as described [23]. Wild-type and IFN-gammaR KO DBA/1 mice were bred in the Experimental Animal Centre of the University of Leuven. The experiments were performed in mice 6 to 10 weeks old, but in each experiment the mutant and wild-type mice were age-matched within 5-day limits. The male : female ratio was kept between 0.8 and 1.3 in each experiment group, unless otherwise mentioned. All animal experiments were approved by the local ethical committee (University of Leuven).
###end p 11
###begin title 12
Induction and clinical assessment of arthritis
###end title 12
###begin p 13
###xml 281 305 275 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium butyricum </italic>
###xml 7 14 <span type="species:ncbi:9031">chicken</span>
###xml 215 218 <span type="species:ncbi:31658">CFA</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 497 501 <span type="species:ncbi:10090">mice</span>
Native chicken CII (Sigma-Aldrich, St Louis, MO, USA) was dissolved at 2 mg/ml in PBS containing 0.1 M acetic acid by stirring overnight at 6degreesC and emulsified in an equal volume of complete Freund's adjuvant (CFA; Difco Laboratories, Detroit, MI, USA) with added heat-killed Mycobacterium butyricum (0.5 mg/ml). IFN-gammaR KO and wild-type mice were sensitised with a single intradermal injection at the base of the tail with 100 mul of the emulsion on day 0. From day 0 after immunisation, mice were examined for signs of arthritis five times a week. The disease severity was recorded with the following scoring system for each limb: score 0, normal; score 1, redness and/or swelling in one joint; score 2, redness and/or swelling in more than one joint; score 3, redness and/or swelling in the entire paw; score 4, deformity and/or ankylosis.
###end p 13
###begin title 14
Media, reagents and antibodies
###end title 14
###begin p 15
All cells were grown in RPMI 1640 (Bio Whittaker Europe, Verviers, Belgium), supplemented with 10% heat-inactivated FCS (Gibco, Paisley, UK), penicillin (100 IU/ml; Continental Pharma, Brussel, Belgium), streptomycin (100 mug/ml; Continental Pharma), 2 mM L-glutamine, 10 mM Hepes (Gibco), 0.1 mM nonessential amino acids (ICN, Asse Relegem, Belgium), 1 mM sodium pyruvate (Gibco) and 50 muM 2-mercaptoethanol (Fluka, AG, Switzerland).
###end p 15
###begin p 16
###xml 307 314 303 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 140 143 <span type="species:ncbi:10116">rat</span>
Anti-CD25 IL-2Ralpha monoclonal antibody was produced by hybridoma PC61 in an INTEGRA CELLine CL1000 (Elscolab, Kruibeke, Belgium) and is a rat IgG1 antibody. The hybridoma supernatant was purified by Protein G-Sepharose chromatography (Amersham Biosciences, Roosendaal, The Netherlands) for administration in vivo.
###end p 16
###begin p 17
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 326 334 326 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Limulus </italic>
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
The hamster monoclonal antibody, directed against the mouse CD3 complex, was prepared from the culture supernatant of 145-2C11 hybridoma cells [28]. The antibodies were purified by affinity chromatography with Protein A-Sepharose (Amersham Biosciences). Batches of anti-CD3 antibody were tested for endotoxin content with the Limulus amebocyte lysate QCL-1000 kit (Bio Whittaker) and were found to contain less than 3 ng/ml endotoxin.
###end p 17
###begin title 18
Cell purification
###end title 18
###begin p 19
###xml 357 358 351 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 513 515 507 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 609 610 603 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 614 616 608 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 623 624 617 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 628 630 622 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 653 655 647 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 801 803 788 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 959 960 946 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 964 966 951 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1015 1016 1002 1003 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1020 1022 1007 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1075 1077 1062 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1300 1301 1287 1288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1305 1307 1292 1294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1406 1407 1393 1394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1411 1413 1398 1400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1478 1479 1465 1466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1483 1485 1470 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1545 1546 1532 1533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1550 1552 1537 1539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1596 1597 1583 1584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1601 1603 1588 1590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 532 537 <span type="species:ncbi:10090">Mouse</span>
Lymph nodes (axillary, inguinal and mesenteric) and spleens were harvested from mice 6 to 8 weeks old. Lymph nodes and spleens were gently cut into small pieces and passed through cell strainers (Becton Dickinson Labware, Franklin Lakes, NJ, USA). Red blood cells were lysed by two consecutive incubations (5 and 3 min at 37degreesC) of the suspension in NH4Cl (0.83% in 0.01 M Tris-HCl, pH 7.2). Remaining cells were washed, resuspended in cold PBS and counted. Lymph node preparations were then enriched for CD4+ T cells with the Mouse T cell CD4 Subset Column Kit (R&D systems, Abingdon, UK). To purify CD4+CD25+ and CD4+CD25- cells, the enriched CD4+ T cells were incubated for 20 min at 4degreesC with FITC-conjugated anti-CD25 and phycoerythrin (PE)-conjugated anti-CD4 antibodies (10 mug per 108 cells) in PBS containing 2% FCS. They were sorted by flow cytometry on a FACS Vantage (Becton Dickinson, San Jose, CA, USA). The resultant purity of the CD4+CD25- population was 99%, whereas the purity of the CD4+CD25+ population varied from 96% to 99%. Alternatively, CD4+ T cells were labelled with PE-conjugated anti-CD25 monoclonal antibody, followed by incubation with magnetic-activated cell sorting (MACS) anti-PE beads (CD25 Microbead Kit; Miltenyi Biotec, Bergisch Gladbach, Germany). CD4+CD25+ T cells were selected on an LS column in a magnetic field and the flow-through was collected as CD4+CD25- T cells. After removal of the column from the magnetic field, CD4+CD25+ T cells were flushed out by a plunger. The purity of the CD4+CD25- population was 99% and the purity of the CD4+CD25+ population varied from 90% to 95%.
###end p 19
###begin p 20
###xml 297 299 297 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
T cell-depleted spleen suspensions were prepared by MACS (Miltenyi Biotec) and used as accessory cells (ACs). For MACS separation, the cell suspension was magnetically labelled with CD90 (Thy1.2) microbeads and passed through a CS separation column, placed in a magnetic field. The unlabelled CD90- cells ran through.
###end p 20
###begin title 21
Flow cytometry
###end title 21
###begin p 22
###xml 31 33 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 522 524 521 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
Single-cell suspensions (5 x 105 cells) were incubated for 15 min with the Fc-receptor-blocking antibodies anti-CD16/anti-CD32 (CD16/CD32; BD Biosciences Pharmingen, San Diego, CA, USA). Cells were washed with PBS containing 2% FCS and stained with the indicated FITC-conjugated antibodies (0.5 mug) for 30 min, washed twice and incubated for 30 min with the indicated PE- or biotin-conjugated antibodies. For the biotin-conjugated antibodies, a third staining step with streptavidin conjugated with peridinin chlorophyll a protein (PerCP) was performed. After washing, propidium iodide (Sigma-Aldrich) was added at a final concentration of 4 mug/ml to distinguish dead cells from living cells. Biotin-conjugated anti-CD25 (7D4), FITC-conjugated anti-CD25 (7D4), FITC-conjugated CD69 (H1.2F3), PE-conjugated anti-CD4 (RM4-5) and PerCP-conjugated streptavidin were purchased from BD Biosciences Pharmingen. FITC-conjugated anti-CD62L (MEL-14) and anti-CD44-FITC (IM7.8.1) were from CALTAG Laboratories (Burlingame, CA, USA).
###end p 22
###begin p 23
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
For intracellular staining with anti-CTLA-4-PE (UC10-4F10-11; BD Biosciences Pharmingen), 106 cells were first labelled with anti-CD25-FITC as described above. Then, cells were fixed, permeabilised and stained with anti-CTLA-4-PE using the Cytofix/Cytopermtrade mark Kit (BD Biosciences Pharmingen) according to the recommendations of the manufacturers.
###end p 23
###begin p 24
Flow-cytometric analysis was performed on a FACScan flow cytometer with Cell Quest software (Becton Dickinson).
###end p 24
###begin title 25
Proliferation assays
###end title 25
###begin p 26
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 8 10 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 23 25 23 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 104 106 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 235 236 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 240 242 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 283 284 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 345 346 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 400 404 387 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 512 516 499 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 557 561 544 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 604 608 591 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 638 642 625 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
CD4+CD25- cells (5 x 104 per well) were cultured in U-bottomed 96-well plates (200 mul) with ACs (5 x 104 per well, 30 Gy gamma-irradiated or treated with mitomycin-C (Sigma-Aldrich)), 3 mug/ml anti-CD3 and the indicated numbers of CD4+CD25+ cells for 48 hours at 37degreesC in 7% CO2. Cultures were pulsed for the last 16 hours with 1 muCi of [3H]TdR and harvested. The suppressive activity of the Treg cells can be presented by plotting the percentage of inhibition (100 x (Radioactivity in condition without Treg cells - Radioactivity in condition with Treg cells)/Radioactivity in condition without Treg cells) against the number of Treg cells.
###end p 26
###begin title 27
Antibody administration
###end title 27
###begin p 28
###xml 6 10 <span type="species:ncbi:10090">mice</span>
###xml 38 41 <span type="species:ncbi:31658">CFA</span>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
DBA/1 mice were immunised with CII in CFA; 13 days after immunisation, the mice were treated every second day with 0.25 mg of anti-CD25 (PC61) or control IgG antibodies, for 4 weeks (injected intraperitoneally).
###end p 28
###begin title 29
Histological examination
###end title 29
###begin p 30
Forelimbs and hindlimbs were fixed in 10% formalin and decalcified with formic acid (31.5% (v/v) formic acid and 13% (w/v) sodium citrate). The paraffin sections were stained with haematoxylin and eosin.
###end p 30
###begin title 31
Measurement of serum anti-CII antibodies
###end title 31
###begin p 32
###xml 208 215 <span type="species:ncbi:9031">chicken</span>
###xml 811 815 <span type="species:ncbi:9925">goat</span>
###xml 821 826 <span type="species:ncbi:10090">mouse</span>
###xml 1446 1450 <span type="species:ncbi:10090">mice</span>
Blood samples were taken from the orbital sinus and were allowed to clot at room temperature for about 1 hour, and at 4degreesC overnight. Individual sera were tested by ELISA for antibodies directed against chicken CII. In brief, ELISA plates (Maxisorb; Nunc, Wiesbaden, Germany) were coated overnight at 4degreesC with native CII (1 mug/ml; 100 mul per well) in coating buffer (50 mM Tris-HCl, pH 8.5, 0.154 mM NaCl), followed by incubation for 2 hours with blocking buffer (50 mM Tris-HCl, pH 7.4, 0.154 mM NaCl and 0.1% caseine) to saturate non-specific binding sites. Serial twofold dilutions of the sera in assay buffer (50 mM Tris-HCl, pH 7.4, 154 mM NaCl and 0.05% Tween 20) were added and incubated for 2 hours at room temperature. The plates were then incubated for 2 hours with peroxidase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Finally, the substrate 3,3',5,5'-tetramethylbenzidine (Sigma-Aldrich) in reaction buffer (100 mM sodium acetate/citric acid, pH 4.9) was added for a 10 min incubation and absorbance was determined at 450 nm. Plates were washed five times between each step with PBS containing 0.05% Tween 20. A serial twofold dilution series of a purified standard was included to permit a calculation of the antibody content of each sample. The standard was purified by affinity chromatography from pooled sera obtained from various arthritic wild-type and IFN-gammaR KO mice.
###end p 32
###begin title 33
Quantitative RT-PCR
###end title 33
###begin p 34
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 17 19 17 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 31 33 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Isolated CD4+CD25+ and CD4+CD25- cells were pelleted and directly used for total RNA isolation, using the Micro-to-Midi Total RNA Purification System (Invitrogen Life Technologies, Carlsbad, CA, USA). Total RNA (1 mug) was used for random primed cDNA synthesis with RAV-2 reverse transcriptase (Amersham, Aylesbury, Bucks., UK). The reaction mixture was incubated for 80 min at 42degreesC and the reverse transcriptase was inactivated by incubating the cDNA samples for 5 min at 95degreesC.
###end p 34
###begin p 35
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
The cDNA samples were then subjected to real-time quantitative PCR, performed in the ABI prism 7700 sequence detector (Applied Biosystems, Foster City, CA) as previously described [29]. The sequences of the forward (-FW) and reverse (-RV) primers and probes (-TP) for beta-actin and Foxp3 were as follows: beta-actin-FW, AGA GGG AAA TCG TGC GTG AC; beta-actin-RV, CAA TAG TGA TGA CCT GGC CG T; beta-actin-TP, CAC TGC CGC ATC CTC TTC CTC CC; Foxp3-FW, CCC AGG AAA GAC AGC AAC CTT; Foxp3-RV, TTC TCA CAA CCA GGC CAC TTG; Foxp3-TP, ATC CTA CCC ACT GCT GGC AAA TGG AGT C; TGF-beta-FW, TGA CGT CAC TGG AGT TGT ACG G; TGF-beta-RV, GGT TCA TGT CAT GGA TGG TGC; TGF-beta-TP, TTC AGC GCT CAC TGC TCT TGT GAC AG. Probes were dual-labelled with 5'-FAM and 3'-TAMRA.
###end p 35
###begin p 36
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 931 933 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
All primers and probes were designed with the assistance of the computer program Primer Express (AB) and were purchased from Eurogentec (Seraing, Belgium). The 5'-nuclease activity of the Taq polymerase was used to cleave a nonextendable dual-labelled fluorogenic probe. Fluorescent emission was measured continuously during the PCR reaction. PCR amplifications were performed in a total volume of 25 mul containing 5 mul of cDNA, 12.5 mul of Universal PCR Master Mix, no AmpErase UNG (AB), each primer at 100 to 300 nM, and the corresponding detection probe at 200 nM. Each PCR amplification was performed in triplicate wells under the following conditions: 94degreesC for 10 min, followed by 40 or 45 cycles at 94degreesC for 15 s and 60degreesC for 1 min. cDNA plasmid standards, consisting of purified plasmid DNA specific for each individual target, were used to quantify the target gene in the unknown samples, as described [29]. All results were normalised to beta-actin and/or hypoxanthine-guanine phosphoribosyltransferase (HPRT) to compensate for differences in the amount of cDNA in all samples. Results were similar whether beta-actin or HPRT was used as the housekeeping gene.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
###xml 20 28 20 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Effect of treatment in vivo with depleting anti-CD25 antibodies on the development of CIA in wild-type DBA/1 mice
###end title 38
###begin p 39
###xml 59 63 59 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 138 142 138 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 558 560 558 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 650 652 650 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 1185 1187 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1188 1190 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1350 1352 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 1548 1550 1544 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 1717 1719 1713 1715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 2169 2171 2165 2167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2192 2193 2188 2189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 2335 2337 2325 2327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2358 2359 2348 2349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 2514 2516 2504 2506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1e</xref>
###xml 2526 2528 2516 2518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1f</xref>
###xml 2911 2913 2901 2903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1g</xref>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 262 265 <span type="species:ncbi:31658">CFA</span>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
###xml 835 839 <span type="species:ncbi:10090">mice</span>
###xml 883 886 <span type="species:ncbi:31658">CFA</span>
###xml 906 910 <span type="species:ncbi:10090">mice</span>
###xml 1132 1136 <span type="species:ncbi:10090">mice</span>
###xml 1179 1183 <span type="species:ncbi:10090">mice</span>
###xml 1260 1264 <span type="species:ncbi:10090">mice</span>
###xml 1384 1388 <span type="species:ncbi:10090">mice</span>
###xml 1475 1479 <span type="species:ncbi:10090">mice</span>
###xml 1676 1680 <span type="species:ncbi:10090">mice</span>
###xml 1886 1890 <span type="species:ncbi:10090">mice</span>
###xml 1965 1969 <span type="species:ncbi:10090">mice</span>
###xml 2061 2065 <span type="species:ncbi:10090">mice</span>
###xml 2315 2319 <span type="species:ncbi:10090">mice</span>
###xml 2462 2466 <span type="species:ncbi:10090">mice</span>
###xml 2618 2622 <span type="species:ncbi:10090">mice</span>
###xml 2658 2662 <span type="species:ncbi:10090">mice</span>
In a first set of experiments we tested the importance of Treg cells in the pathogenesis of CIA by rendering wild-type mice deficient in Treg cells by treating the mice with depleting anti-CD25 antibody. Starting from day 11 or 13 after immunisation with CII in CFA, wild-type DBA/1 mice were treated every second day with anti-CD25 antibodies or control IgG. In a first experiment, female mice were chosen because these are only moderately sensitive to CIA [30,31], so that we would be able to detect both increased and decreased disease severity after CD25+ cell depletion. Blood samples were taken at intervals to confirm the depletion of the CD25+ population (Fig. 1a). In control-treated mice, the development of arthritis (day of onset, incidence and mean limb score) was reminiscent of our previously reported findings in which mice received a single immunisation with CII in CFA [20]. In contrast, mice treated with the anti-CD25 antibodies developed a significantly more severe arthritis with a higher incidence and earlier onset than those receiving control IgG1 (Fig. 1b). In fact, the disease course in antibody-treated mice was very similar to that of IFN-gammaR KO mice [20-22]. The results were confirmed in an additional experiment with female mice. A third experiment was also performed on male animals. The data are plotted in Fig. 1c. Here again, anti-CD25-treated mice developed a higher incidence and a more severe form of arthritis than control-treated mice, whereas the onset of arthritis was not significantly earlier (Fig. 1d). The data from the three experiments were pooled and the percentages of limbs with the different scores from only arthritic mice in the two groups are shown in Fig. 1d. It can be seen that, at an early time point (day 27 after immunisation), the highest scores of arthritis (scores 3 and 4) were already present in anti-CD25-injected mice, but not yet in their control counterparts. On day 40 after immunisation, mice treated with anti-CD25 developed more limbs with a maximum score of 4 than control-treated mice. The mean limb score on the two days for the two groups are indicated and are significantly different (P < 0.05, Mann-Whitney U-test). The mean number of involved limbs, +/- SEM, on day 40 was 2.8 +/- 0.2 and 2.2 +/- 0.2 for the treated and control mice, respectively (P = 0.07; Mann-Whitney U-test). Representative pictures of the most severe case of arthritis of anti-CD25-injected and control mice on day 25 after immunisation are shown in Fig. 1e and Fig. 1f, respectively. To ensure that the more severe form of arthritis in the anti-CD25-treated mice was not merely due to oedema, some mice were killed at day 42 for histological evaluation. The presence of hyperplasia and infiltration of immunocompetent cells in the synovium, pannus formation and osteoclast-like multinucleated giant cells confirmed the authenticity of arthritis (Fig. 1g).
###end p 39
###begin p 40
###xml 147 151 <span type="species:ncbi:10090">mice</span>
On day 35 after immunisation, the titres of collagen-specific antibodies in the sera were determined. No differences in antibody levels in sera of mice treated with anti-CD25 or control IgG could be detected (data not shown).
###end p 40
###begin title 41
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 32 34 32 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 35 39 35 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Number and phenotype of CD4+CD25+ Treg cells in IFN-gammaR KO and wild-type mice
###end title 41
###begin p 42
###xml 17 21 17 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 176 177 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 181 183 177 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 499 501 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 502 504 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 702 703 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 723 724 707 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 728 730 712 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 737 738 721 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 742 744 726 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 843 844 823 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 848 850 828 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 980 982 956 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1088 1090 1064 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1248 1250 1220 1222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1402 1404 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1405 1407 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 302 305 <span type="species:ncbi:31658">CFA</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
###xml 897 901 <span type="species:ncbi:10090">mice</span>
###xml 1205 1209 <span type="species:ncbi:10090">mice</span>
###xml 1397 1400 <span type="species:ncbi:31658">CFA</span>
To test whether Treg cells might be less numerous in IFN-gammaR KO than in wild-type mice - because this might explain the differences in susceptibility to CIA - we counted CD4+CD25+ cells in thymus, lymph nodes and spleen by flow cytometry. IFN-gammaR KO and wild-type mice were immunised with CII in CFA on day 0. Thymocytes, splenocytes and lymph node cells were obtained on day 21, a time point at which the difference in severity of arthritis between the two groups of mice is most pronounced [20-22]. Groups of naive IFN-gammaR KO and wild-type mice were also included. A typical CD4/CD25 staining pattern of thymocytes and lymph node cells from IFN-gammaR KO and wild-type mice is shown in Fig. 2; percentages of CD4+CD25+ and CD4+CD25- cells are indicated. It can be seen that IFN-gammaR KO mice did not have smaller proportions of CD4+CD25+ cells in the thymus and lymph nodes. Immunised mice, whether wild-type or IFN-gammaR KO, had rather lower proportions of total CD4+ cells than naive counterparts (for example 31% versus 50% in wild types). However, the real numbers of CD4+ cells per organ were in fact higher after immunisation and did not differ in IFN-gammaR KO from those in wild-type mice. In fact, the lower percentages of CD4+ cells after immunisation were due to a still larger expansion of the myelopoietic population, a well-recognised phenomenon arising from the use of CFA [22,32].
###end p 42
###begin p 43
###xml 44 45 44 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 118 120 118 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 275 276 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 280 282 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 354 356 350 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 373 374 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 495 496 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 500 502 496 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 556 558 552 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 597 598 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 601 603 597 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 615 616 611 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 619 621 615 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 656 657 652 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 737 738 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 742 744 734 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 806 807 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
###xml 437 442 <span type="species:ncbi:10090">mouse</span>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
###xml 794 798 <span type="species:ncbi:10090">mice</span>
When over a total of six experiments (Table 1) the numbers of CD4+CD25+ cells were expressed as fractions of total CD4+ cell numbers, it appeared that spleens and lymph nodes of IFN-gammaR KO mice, naive as well as immunised ones, contained slightly higher percentages of CD4+CD25+ cells. In spleens and lymph nodes of wild-type mice, 5 to 10% of the CD4+ T cells were CD25+, conforming to previously published figures obtained in other mouse strains. Thymuses contained lower percentages of CD4+CD25+ cells. A possible explanation might be that thymic CD4+ T cell populations contain not only CD4+CD8- but also CD4+CD8+ cells, the latter being mostly CD25-. In the peripheral lymphoid organs of IFN-gammaR KO mice, the percentage of CD4+CD25+ cells was higher (7 to 14%) than in the wild-type mice (Table 1).
###end p 43
###begin p 44
###xml 39 43 39 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 137 139 137 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 214 218 210 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 321 322 317 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 326 328 322 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 439 443 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a,b</xref>
###xml 568 569 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 573 575 565 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 741 742 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 746 748 734 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 939 943 923 927 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 973 977 957 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1054 1055 1038 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1059 1061 1043 1045 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1068 1069 1052 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1073 1075 1057 1059 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1193 1194 1173 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1198 1200 1178 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1320 1321 1300 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1325 1327 1305 1307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1471 1472 1447 1448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1476 1478 1452 1454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1597 1599 1569 1571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 1678 1682 1650 1654 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1705 1706 1677 1678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1710 1712 1682 1684 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 775 779 <span type="species:ncbi:10090">mice</span>
###xml 805 809 <span type="species:ncbi:10090">mice</span>
###xml 1171 1175 <span type="species:ncbi:10090">mice</span>
###xml 1297 1301 <span type="species:ncbi:10090">mice</span>
###xml 1429 1433 <span type="species:ncbi:10090">mice</span>
###xml 1513 1517 <span type="species:ncbi:10090">mice</span>
###xml 1586 1590 <span type="species:ncbi:10090">mice</span>
Because CD25 is expressed not only by Treg cells but also by other recently activated T cells, the slightly higher proportion of CD4+CD25+ cells in IFN-gammaR KO mice is not synonymous with a higher proportion of Treg cells. In fact, even a lower proportion of such cells cannot be excluded. We therefore compared the CD4+CD25+ T cells from IFN-gammaR KO and wild-type DBA/1 mice for expression of various other activation markers. Figure 3a,b shows flow-cytometric expression patterns of CD69, CD62L, CD44 and cytolytic T lymphocyte-associated antigen (CTLA-4) in CD4+CD25+ T cells from naive and immunised IFN-gammaR KO and wild-type mice. No major differences in expression levels of these activation markers could be detected between CD4+CD25+ T cells from IFN-gammaR KO mice and those from wild-type mice, whether naive or immunised. Thus, this analysis did not provide evidence for different proportions of any cell type, including Treg cells. A specific marker for Treg cells is Foxp3. We determined mRNA for this marker by quantitative PCR in CD4+CD25+ and CD4+CD25- cells, sorted from the lymph node cells of naive or immunised IFN-gammaR KO and wild-type DBA/1 mice at day 21. In CD4+CD25- cells Foxp3 mRNA levels were extremely low (less than 6), and not different between one group of mice and the other. CD4+CD25+ cells, in contrast, displayed high expression levels. In cells from naive IFN-gammaR KO and wild-type mice, levels were comparable. However, CD4+CD25+ T cells of immunised IFN-gammaR KO mice contained levels of Foxp3 that were one-third of those of wild-type mice (Fig. 3c). This lower expression level might be indicative of a smaller proportion of Treg cells in the sorted CD4+CD25+ cell population or of a lower expression level per cell. To distinguish between these alternatives, a tagging anti-Foxp3 antibody would be needed.
###end p 44
###begin p 45
###xml 90 91 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 95 97 91 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 145 149 141 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 40 44 <span type="species:ncbi:10090">mice</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
Thus, after immunisation, IFN-gammaR KO mice possessed a slightly higher percentage of CD4+CD25+ cells than wild-type mice. However, the actual Treg cells present in this population might be considerably less numerous or might be qualitatively different so as to express less Foxp3.
###end p 45
###begin title 46
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 43 47 43 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Reduced suppressive activity of CD4+CD25+ Treg cells in arthritic IFN-gammaR KO mice
###end title 46
###begin p 47
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 28 30 28 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 31 35 31 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 139 141 139 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 142 146 142 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 152 160 152 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 206 208 206 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 223 225 223 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 241 245 241 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 344 348 344 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 372 376 372 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a,c</xref>
###xml 482 484 482 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 586 590 586 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 655 659 651 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 705 714 701 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
To characterise the CD4+CD25+ Treg cells functionally, we measured their ability to suppress the anti-CD3-induced proliferation of CD4+CD25- Teff cells in vitro. The experiments were performed with CD4+CD25+ cells, CD4+CD25- cells and ACs. Treg suppressive activity was presented by plotting the percentage of inhibition against the number of Treg cells. As shown in Fig. 4a,c, the patterns of inhibition in naive IFN-gR KO and wild-type mice were very similar: in both cases 2 x 104 purified CD4+CD25+ cells were able to inhibit more than 90% of the proliferative response of 5 x 104 Teff cells. This result indicates that IFN-gamma is not required for Treg cells to be able to suppress anti-CD3-induced in vitro proliferation.
###end p 47
###begin p 48
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 89 91 89 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 219 220 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 224 226 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 234 238 230 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 355 357 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 415 417 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 496 500 492 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 536 537 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 541 543 537 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 669 671 665 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 674 675 670 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 679 681 675 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 764 766 760 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 769 770 765 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 774 776 770 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 822 823 818 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 827 829 823 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 947 949 939 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 952 953 944 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 957 959 949 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 993 997 985 989 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 1104 1105 1096 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1109 1111 1101 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1190 1191 1178 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1195 1197 1183 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1224 1226 1212 1214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 1236 1238 1224 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 1241 1242 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1246 1248 1234 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 143 146 <span type="species:ncbi:31658">CFA</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
###xml 803 807 <span type="species:ncbi:10090">mice</span>
###xml 864 868 <span type="species:ncbi:10090">mice</span>
###xml 939 943 <span type="species:ncbi:10090">mice</span>
###xml 1146 1150 <span type="species:ncbi:10090">mice</span>
In a separate set of seven experiments we investigated the suppressive effect of CD4+CD25+ cells from mice that had been immunised with CII in CFA. IFN-gammaR KO and wild-type DBA/1 mice were immunised on day 0, and CD4+CD25+ cells, Teff cells and ACs were isolated on day 21 after immunisation. The data of the individual experiments are plotted in Fig. 4b and the means of the seven experiments are shown in Fig. 4c. It can be seen that the capacity to suppress TCR-triggered proliferation of Teff cells was significantly lower in CD4+CD25+ cells isolated from immunised mice than in those of naive animals. Indeed, to obtain 40% inhibition of proliferation, 4.5 x 103 CD4+CD25+ cells from immunised wild-type mice were required, in comparison with only 1.5 x 103 CD4+CD25+ cells from naive wild-type mice. Moreover, CD4+CD25+ cells from immunised IFN-gammaR KO mice were significantly less suppressive than those of immunised wild-type mice: 104 CD4+CD25+ cells were necessary to decrease Teff cell proliferation by 40%. In an additional experiment we verified whether the deficit in inhibition by CD4+CD25+ cells from immunised IFN-gammaR KO mice could be corrected by adding excess CD4+CD25+ cells. However, with 2 x 104 and 4 x 104 CD4+CD25+ cells the inhibition on T cell proliferation was 64.6% and 65.8%, respectively, indicating that a plateau level of suppressive activity had been reached.
###end p 48
###begin title 49
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Normal levels of TGF-beta in IFN-gammaR KO and wild-type mice
###end title 49
###begin p 50
###xml 104 108 101 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 115 117 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 118 120 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 121 123 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 208 210 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 458 462 437 441 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 546 554 522 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 636 640 609 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 802 803 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 807 809 777 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1069 1073 1023 1027 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 1149 1153 1103 1107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1159 1163 1113 1117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 1402 1404 1345 1347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 1405 1409 1348 1352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1488 1495 1428 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo</italic>
###xml 1622 1625 1558 1561 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg</sub>
###xml 1628 1632 1564 1568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 1904 1908 1825 1829 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 383 387 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
###xml 844 848 <span type="species:ncbi:10090">mice</span>
###xml 892 896 <span type="species:ncbi:10090">mice</span>
###xml 1216 1220 <span type="species:ncbi:10090">mice</span>
###xml 1435 1439 <span type="species:ncbi:10090">mice</span>
###xml 1556 1560 <span type="species:ncbi:10090">mice</span>
###xml 1754 1758 <span type="species:ncbi:10090">mice</span>
###xml 1819 1823 <span type="species:ncbi:10090">mice</span>
###xml 1943 1947 <span type="species:ncbi:10090">mice</span>
Several studies have shown the critical role of TGF-beta in the induction of Foxp3 and the activity of Treg cells [10,33,34]. Because IFN-gamma and TGF-beta act antagonistically with each other (reviewed in [35]), it is possible that TGF-beta is upregulated in wild-type mice as a homeostatic response to IFN-gamma produced by their activated T cells, and similarly in IFN-gammaR KO mice the decreased Foxp3 levels and the decreased suppressive activity of Treg cells might be due to inadequate amounts of TGF-beta produced in the co-cultures or in vivo in mice. We therefore analysed the expression of TGF-beta by quantitative PCR in Treg cells as well as in co-cultures and in spleens of naive and immunised mice. The following results were obtained. First, the levels of TGF-beta from the sorted CD4+CD25+ cells from immunised IFN-gammaR KO mice were not different from those of wild-type mice (normalised TGF-beta mRNA levels were 179 +/- 16 and 193 +/- 22, respectively; mean +/- SEM for three measurements). Second, because TGF-beta might be produced by ACs (or Teff cells), quantitative PCR was performed on cells obtained from co-cultures (Treg plus Teff plus ACs) from immunised IFN-gammaR KO and wild-type mice. It was found that the levels of TGF-beta were even increased in IFN-gammaR KO cells in comparison with wild-type cells (2,184 versus 1,574, respectively, in the condition of 2 x 104 Treg cells, in a pool of eight mice). Third, the TGF-beta levels were also analysed ex vivo; that is, in spleen tissue from IFN-gammaR KO and wild-type mice at day 21 after immunisation (thus at a time point at which Treg, Teff and ACs were isolated). Here again, the TGF-beta levels were found to be slightly increased in spleens from IFN-gammaR KO mice (816 +/- 129 and 633 +/- 40 for IFN-gammaR KO and wild-type mice, respectively). If these results are taken together, the defective activity of Treg cells from arthritic IFN-gammaR KO mice (in comparison with those from wild-type animals) seems not to be associated with a defective TGF-beta production.
###end p 50
###begin p 51
###xml 266 270 259 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
It was notable that the TGF-beta levels were higher in immunised mice than in their naive counterparts (for example, 633 +/- 40 and 205 +/- 19 for immunised and naive wild-type mice, respectively). These data suggest that the differences in suppressive activity of Treg cells from immunised versus naive mice cannot be explained by differences in the TGF-beta production.
###end p 51
###begin title 52
###xml 1 5 1 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 40 44 <span type="species:ncbi:10090">mice</span>
Treg cells from immunised IFN-gammaR KO mice have the capacity to inhibit proliferation responses
###end title 52
###begin p 53
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 59 61 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 211 215 207 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 330 331 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 335 336 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 341 342 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 346 348 342 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 503 504 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
We next investigated whether the lower capacity of CD4+CD25+ cells from IFN-gammaR KO mice to downregulate proliferation responses is due to an intrinsic defect or to an altered activity of surrounding ACs and Teff cells. We measured the inhibition of anti-CD3-induced proliferation in co-cultures differently reconstituted of CD4+CD25+, CD4+CD25- and ACs, derived either from the same or from different immunised wild-type or immunised IFN-gammaR KO mice. The combinations tested are indicated in Fig. 5.
###end p 53
###begin p 54
###xml 259 260 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 264 266 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 497 501 481 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 560 564 540 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 627 628 607 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 632 634 612 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 635 639 615 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 671 675 651 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 83 88 <span type="species:ncbi:10090">mouse</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
As expected, when all cells in the reconstituted co-cultures were of IFN-gammaR KO mouse origin, suppressive activity was less than when all cells were of wild-type origin. In co-cultures of mixed composition, suppressive activity of IFN-gammaR KO-derived CD4+CD25+ cells was less than that of the wild type only when ACs were from IFN-gammaR KO origin, but not when they were of wild-type origin. However, such ACs of IFN-gammaR KO mice were unable to reduce the suppressive effect of wild-type Treg cells against wild-type or IFN-gammaR KO (data not shown) Teff cells. These data demonstrate that the defect in inhibiting CD4+CD25- Teff cells acquired the presence of Treg cells from immunised IFN-gammaR KO mice in combination with their autologous ACs.
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 231 233 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 234 236 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 237 239 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 240 242 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 312 314 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 752 754 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 755 757 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 905 907 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1017 1021 993 997 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1089 1093 1065 1069 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1169 1173 1145 1149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1347 1351 1319 1323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 530 533 <span type="species:ncbi:31658">CFA</span>
###xml 598 601 <span type="species:ncbi:31658">CFA</span>
###xml 1192 1196 <span type="species:ncbi:10090">mice</span>
###xml 1275 1279 <span type="species:ncbi:10090">mice</span>
We and others have previously demonstrated that IFN-gamma(R) KO mice show an accelerated and more severe from of arthritis than their wild-type counterparts, indicating that endogenous IFN-gamma acts as a protective factor in CIA [20,21,24,25]. Because CIA has been defined as a Th1-driven disease (reviewed in [17]), the protective effect of IFN-gamma in CIA constitutes an enigma that compromises the Th1/Th2 paradigm as a basis for explaining the regulation of autoimmune diseases. A clue to the enigma seemed to be the use of CFA in the induction procedure of CIA. In the absence of IFN-gamma, CFA induces an extensive extramedullary myelopoiesis that goes together with an even more pronounced Th1 cytokine profile than in wild-type counterparts [22,36]. The data suggest that IFN-gamma can, under certain circumstances, be a strong Th2 inducer, a finding that has recently been confirmed by others [37]. Here, we tested the hypothesis that this protective action of IFN-gamma is due to a stimulatory effect on Treg cells. Specifically, we addressed the following two questions. Are Treg cells important in modulating CIA? And, because we found that depletion of Treg cells in wild-type mice increased the severity of CIA, can the higher susceptibility of IFN-gammaR KO mice to CIA be explained by defects in the number or function of their Treg cells?
###end p 56
###begin p 57
###xml 61 65 61 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 303 305 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 306 308 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 336 340 332 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 510 512 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 794 798 790 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 967 969 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1227 1231 1223 1227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1303 1305 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1435 1436 1431 1432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1440 1442 1436 1438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1560 1561 1556 1557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1565 1567 1561 1563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1568 1572 1564 1568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1610 1612 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 129 132 <span type="species:ncbi:31658">CFA</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
As to the first question, we found that administration of a Treg cell-depleting anti-CD25 antibody to wild-type DBA/1 mice after CFA-assisted immunisation with CII resulted in accelerated and more severe arthritis. In fact, the disease course in these mice was comparable to that in IFN-gammaR KO mice [20-23]. The actual depletion of Treg cells was monitored by flow cytometry, and the authenticity of arthritis was verified histopathologically. These results are in line with those of Morgan and colleagues [26], who showed that the administration of depleting anti-CD25 antibody before immunisation (days -28, -24, -21 and -14) hastened the onset of severe CIA. Because in our experiments antibodies were administered starting from day 11 or day 13 after immunisation, we can conclude that Treg cells are important in the pathogenesis of CIA, not only in the immunisation phase but also in the effector phase. In contrast to the findings of Morgan and colleagues [26], the accelerated and more severe course of arthritis was, in our experiments, not accompanied by a higher concentration of anti-collagen II antibodies, possibly due to the different regimen of anti-CD25 treatment. Indirect evidence for the involvement of Treg cells in the pathogenesis of CIA comes from data of Min and colleagues [38]. They found that the immune tolerance induced by oral feeding of CII before induction of CIA was mediated by IL-10-producing CD4+CD25+ T cells. Notably, in proteoglycan-induced arthritis, another model of autoimmune arthritis, it has been shown that CD4+CD25+ Treg cells might not have a critical role [39]. This might result from the use of a different auto-antigen.
###end p 57
###begin p 58
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 52 54 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 72 76 72 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 200 204 196 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 358 359 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 363 365 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 389 391 381 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 460 462 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 669 673 661 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 725 726 717 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 730 732 722 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 793 795 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 796 798 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 982 983 974 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 987 989 979 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 497 501 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
To address the second question, we compared CD4+CD25+ cell numbers and Treg cell function in IFN-gammaR KO DBA/1 mice with those in wild-type mice. According to our hypothesis we expected numbers of Treg cells in IFN-gammaR KO mice to be lower. Counter to this expectation, in each of the six experiments done, we found a trend for a higher proportion of CD4+CD25+ T cells in the total CD4+ cell population. This was true for thymic, splenic and lymph node CD4+ cells, in both naive and immunised mice. Analysis of all data as one set revealed a significant difference of about 30% and 20% in naive and immunised mice, respectively. CD25 is not an exclusive marker of Treg cells: especially in immunised mice, part of the CD4+CD25+ population might be effector rather than regulatory T cells [40,41]. Therefore, to exclude the possibility that we were comparing two completely different populations, we performed additional flow-cytometric characterisation studies on pre-sorted CD4+CD25+ cells.
###end p 58
###begin p 59
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 207 211 203 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 306 310 302 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 332 336 328 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 381 383 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 408 412 404 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 465 466 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 470 472 466 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 473 477 469 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 544 548 540 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 644 645 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 649 651 645 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 916 920 904 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 963 967 951 955 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 783 787 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
Expression of CD44, CD69, CTLA-4 and CD62L in CD4+CD25+ cells from IFN-gammaR KO mice did not differ from expression in cells from corresponding wild-type mice, whether naive or immunised. However, because Treg cells display an activated phenotype, activation markers might not be adequate to distinguish Treg cells from activated Teff cells. According to Fontenot and colleagues [42] a specific marker for Treg cells is Foxp3, because it is highly expressed in CD4+CD25+ Treg cells and is virtually undetectable in both resting and activated Teff cells. We examined Foxp3 expression by determining mRNA levels with PCR. After immunisation, CD4+CD25+ cells contained lower levels of Foxp3 mRNA than those of their naive counterparts. Moreover, mRNA levels in immunised IFN-gammaR KO mice were less than one-third of those in their wild-type counterparts, indicating that IFN-gammaR KO mice have a smaller number of Treg cells or that expression of Foxp3 in each Treg cell is lower.
###end p 59
###begin p 60
###xml 33 35 33 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 167 169 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 170 174 170 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 247 248 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 252 254 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Recently, Bruder and colleagues [43] have shown linked expression of neuropilin-1 and Foxp3, thereby identifying neuropilin-1 as a specific surface marker for CD4+CD25+ Treg cells able to distinguish them from both naive and recently activated CD4+CD25+ non-regulatory T cells.
###end p 60
###begin p 61
###xml 26 28 26 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 68 72 68 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 579 581 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 582 584 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
Nishibori and colleagues [44] demonstrated impaired development of Treg cells in naive signal transduction and activators of transcription (STAT)-1-deficient mice, associated with an increased susceptibility to autoimmune disease. Because IFN-gamma is among the strongest activators of STAT-1, these observations seem to conflict with ours. However, several cytokines, other than IFN-gamma, can also activate STAT-1, including IFN-alpha, IFN-beta, IL-6, IL-9, IL-11, oncostatin M, leukaemia inhibitory factor and the chemokines RANTES and macrophage inflammatory protein 1alpha [45,46].
###end p 61
###begin p 62
###xml 30 34 30 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 126 127 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 131 133 127 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 166 167 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 171 173 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 174 178 170 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 307 308 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 312 314 308 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 315 319 311 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 354 355 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 359 361 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 563 567 559 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 726 727 714 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 731 733 719 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 734 738 722 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 805 809 793 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 794 798 <span type="species:ncbi:10090">mice</span>
###xml 892 896 <span type="species:ncbi:10090">mice</span>
###xml 983 987 <span type="species:ncbi:10090">mice</span>
To determine whether overall Treg cell activity would be lower in IFN-gammaR KO mice, we co-cultured increasing numbers of CD4+CD25+ T cells with fixed numbers of CD4+CD25- Teff cells and ACs in the presence of anti-CD3 antibody. We observed a dose-dependent inhibition of the proliferative responses by CD4+CD25+ Treg cells. By estimating numbers of CD4+CD25+ cells required to attain a selected level of suppression, we could compare suppressive activity in the different groups of mice. In naive mice, the inhibition curves were almost identical, whether the Treg cells were derived from wild-type or IFN-gammaR KO mice, indicating that endogenous IFN-gamma is not an important regulator of the function of constitutive CD4+CD25+ Treg cells. In co-cultures of cells from immunised wild-type mice, the Treg suppressive capacity was about one-third of that in those from corresponding naive mice, and a further halving was noted in co-cultures of cells from immunised IFN-gammaR KO mice.
###end p 62
###begin p 63
###xml 43 47 43 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 318 319 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 323 325 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 326 330 326 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 433 437 433 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 888 890 884 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 891 895 887 891 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1052 1056 1048 1052 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1306 1310 1294 1298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 402 405 <span type="species:ncbi:31658">CFA</span>
###xml 711 714 <span type="species:ncbi:31658">CFA</span>
###xml 796 800 <span type="species:ncbi:10090">mice</span>
###xml 1112 1116 <span type="species:ncbi:10090">mice</span>
###xml 1123 1126 <span type="species:ncbi:31658">CFA</span>
The observation that immunisation renders Treg cells less suppressive is in line with results of Pasare and Medzhitov [47], who found that microbial triggering of the Toll-like receptor (TLR) pathway by lipopolysaccharide or CpG, which are ligands for TLR4 and TLR9, respectively, blocked the suppressive effect of CD4+CD25+ Treg cells. Because mycobacteria also contain TLR ligands, immunisation with CFA can be expected to affect Treg cell activity similarly. The decrease in suppressive activity that takes place after TLR4 or TLR9 triggering was found to be dependent on IL-6 production [47]. It might therefore be of interest to note that in our experiments, IL-6 production was enhanced after exposure to CFA-assisted immunisation, and this effect was even more pronounced in IFN-gammaR KO mice (P Matthys, unpublished data). This could provide an explanation for the fact that CD25+ Treg cells are totally functional before immunisation but lose (part of) their function after immunisation. However, the most important observation is the lower Treg suppressive capacity in IFN-gammaR KO than in wild-type mice after CFA-assisted immunisation, because this supports our hypothesis that the protective effect of endogenous IFN-gamma against CIA could be mediated in part by its stimulatory effect on Treg cells.
###end p 63
###begin p 64
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
Because the disease is barely detectable in wild-type mice on day 21 after immunisation, we investigated whether the decreased suppressive activity in immunised wild-type mice was further downregulated at a later time point (namely, day 35 after immunisation, when most of the animals show symptoms of arthritis). However, suppressive activity was not further downregulated to the level seen in homogeneous IFN-gammaR KO co-cultures, but was comparable to that seen in co-cultures from immunised wild-type mice on day 21 after immunisation (maximal inhibition 60%; data not shown). This indicates that the low suppressive activity as evident in immunised IFN-gammaR KO mice is restricted to conditions under which IFN-gamma is abrogated.
###end p 64
###begin p 65
###xml 77 81 77 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 255 259 247 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 443 451 427 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 593 594 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 598 600 582 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 658 662 638 642 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 751 752 731 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 756 758 736 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 802 806 778 782 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 990 991 958 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 995 997 963 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1002 1006 970 974 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 1249 1253 1209 1213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1280 1284 1240 1244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 1322 1330 1282 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1497 1501 1449 1453 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 1041 1045 <span type="species:ncbi:10090">mice</span>
###xml 1097 1101 <span type="species:ncbi:10090">mice</span>
###xml 1175 1179 <span type="species:ncbi:10090">mice</span>
###xml 1425 1429 <span type="species:ncbi:10090">mice</span>
###xml 1452 1456 <span type="species:ncbi:10090">mice</span>
The implication is that the CIA immunisation schedule induces a decrease in Treg activity and that endogenous IFN-gamma largely counteracts this decrease. It therefore becomes important to know by what mechanism, direct or indirect, IFN-gamma influences Treg cell function. Addition of anti-IFN-gamma antibody to the co-cultures failed to affect suppressive activity (data not shown), indicating that the relevant IFN-gamma effect takes place in vivo before sampling of the T cells. To examine the role of the different cell components, we tested suppressive activity in mixed co-cultures. CD4+CD25+ cells from immunised IFN-gammaR KO mice, confronted with Teff cells and ACs from immunised wild-type mice, were not less suppressive than wild-type CD4+CD25+ confronted with wild-type or IFN-gammaR KO Teff cells and ACs. This suggests that lower levels of suppression in homogeneous IFN-gammaR KO cultures result in part from the presence of IFN-gammaR KO-derived ACs. And, indeed, when CD4+CD25+ and Teff cells from immunised IFN-gammaR KO mice were co-cultured with ACs from immunised wild-type mice, suppressive activity was not inhibited. Finally, ACs from IFN-gammaR KO mice by themselves were unable to downregulate the activity of wild-type Treg cells acting on wild-type Teff cells. We therefore conclude that the in vivo effect of endogenous IFN-gamma that accounts for the greater suppressive activity in wild-type mice than in IFN-gammaR KO mice concerns reprogramming of both ACs and Treg cells.
###end p 65
###begin p 66
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 16 18 16 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 146 150 142 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 270 271 266 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 275 277 271 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 357 361 349 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 401 405 393 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 430 431 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 435 437 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 526 530 514 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 561 562 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 566 568 554 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 626 630 614 618 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 694 695 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 699 701 687 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
Because CD4+CD25+ T cells from immunised IFN-gammaR KO mice were not less suppressive than those of immunised wild-type mice in co-cultures with Teff cells and ACs from immunised wild-type mice, we can refute the proposition that the lower expression of Foxp3 in the CD4+CD25+ population from immunised IFN-gammaR KO mice is due to a smaller proportion of Treg cells and a larger number of activated Teff cells. Indeed, if the CD4+CD25+ population from immunised IFN-gammaR KO mice contained a higher proportion of activated Teff cells, suppression by these CD4+CD25+ cells should be lower, irrespective of the origin of the Teff cells and ACs. Another argument is that the addition of more CD4+CD25+ cells failed to improve suppression in co-cultures of cells from immunised IFN-gammaR KO mice. Our data are therefore more in line with the proposition of a lower Foxp3 expression level per cell.
###end p 66
###begin p 67
###xml 66 70 66 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 178 180 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 227 229 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 485 489 468 472 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 533 537 516 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 543 547 526 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 685 689 664 668 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 695 704 674 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 707 715 686 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 829 830 805 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 834 836 810 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 879 881 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 965 966 941 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 970 972 946 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1205 1209 1181 1185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1357 1361 1329 1333 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 1421 1425 1389 1393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 1252 1256 <span type="species:ncbi:10090">mice</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
###xml 1394 1398 <span type="species:ncbi:10090">mice</span>
Expression of Foxp3 could be downregulated by the interaction of Treg cells with ACs. ACs might be source of TGF-beta, which has been described to convert naive T cells into CD25+ suppressor cells by inducing Foxp3 expression [48]. Because IFN-gamma and TGF-beta act antagonistically with each other, the low levels of Foxp3 in arthritic IFN-gammaR KO mice might be due to inadequate amounts of TGF-beta produced by ACs or other cells. However, quantitative PCR performed on isolated Treg cells, on cells obtained from co-cultures (Treg plus Teff plus ACs) and on splenocytes from immunised IFN-gammaR KO and wild-type mice does not support the concept that the defective activity of Treg cells in vitro or in vivo is due to defects in the production of TGF-beta. ACs have also been shown to be able to reverse suppression by CD4+CD25+ cells through the GITR/GITR-ligand system [49]. GITR (glucocorticoid-induced tumour necrosis factor receptor) is expressed on CD4+CD25+ T cells; GITR-ligand is initially upregulated on activated APCs. It remains to be determined whether this process involves a downregulation of Foxp3 expression. This or a similar mechanism might take place during the interaction of Treg cells and ACs from immunised IFN-gammaR KO mice. Co-cultures with ACs of immunised wild-type mice might possibly normalise Foxp3 expression in the Treg cells of immunised IFN-gammaR KO mice, together with their Treg suppressive activity.
###end p 67
###begin title 68
Conclusions
###end title 68
###begin p 69
###xml 96 100 96 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 178 182 178 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 408 412 408 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 602 606 594 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 804 808 788 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 402 405 <span type="species:ncbi:31658">CFA</span>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
In conclusion, our experiments support a pathogenesis model that ascribes an important role to Treg cells as moderators of the disease course in CIA. In particular we show that Treg cells fulfil this role not only during the induction phase but also during the effector phase of the autoimmune response. Furthermore, we were able to refine the model by showing that, after the immunisation with CII in CFA, Treg cells lose part of their suppressive potential. This effect is more pronounced in IFN-gammaR KO than in wild-type mice, indicating that, in this system, IFN-gamma acts as an upregulator of Treg activity, which might be part of the explanation for the well-known protective effect of endogenous IFN-gamma. Finally, we present evidence that the mechanism underlying the effect of IFN-gamma on Treg cell activity is exerted in part via ACs.
###end p 69
###begin title 70
Abbreviations
###end title 70
###begin p 71
###xml 623 627 607 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 702 706 686 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 23 26 <span type="species:ncbi:31658">CFA</span>
###xml 214 218 <span type="species:ncbi:9913">calf</span>
ACs = accessory cells; CFA = complete Freund's adjuvant; CIA = collagen-induced arthritis; CII = collagen type II; CTLA = cytolytic T lymphocyte-associated antigen; ELISA = enzyme-linked immunosorbent assay; fetal calf serum = FCS; FITC = fluorescein isothiocyanate; GITR = glucocorticoid-induced tumour necrosis factor receptor; IFN-gamma = interferon-gamma; IFN-gammaR KO = interferon-gamma receptor knock-out; IL = interleukin; MACS = magnetic-activated cell sorting; PBS = phosphate-buffered saline; RT-PCR = reverse transcriptase polymerase chain reaction; STAT = signal transduction and activators of transcription; Teff = effector T; TGF = transforming growth factor; TLR = Toll-like receptor; Treg = regulatory T.
###end p 71
###begin title 72
Competing interests
###end title 72
###begin p 73
The author(s) declare that they have no competing interests.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
###xml 201 210 201 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
BDK, HK and TM performed the CIA induction and evaluation. HK, MVB and GL performed the cell purification. DB performed the quantitative PCR. TM and HK performed the flow cytometry. BDK and HK did the in vitro experiments. HK, GL and PM designed the study. All authors participated in the interpretation of the data. HK, AB, GL and PM prepared the manuscript. All authors read and approved the final manuscript.
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
We thank C Dillen, E Dilissen, W Landuyt and O Rutgeerts for excellent assistance and helpful discussions. This work was supported by grants from the Fund of Scientific Research Flanders (FWO Vlaanderen), from the Regional Government of Flanders (GOA Program), and from the Belgian Federal Government (Interuniversity Network for Fundamental Research, IUAP). PM and DB are postdoctoral research fellows of the FWO Vlaanderen, and HK holds a fellowship from the FWO Vlaanderen.
###end p 77
###begin article-title 78
A paragon of self-tolerance: CD25+CD4+ regulatory T cells and the control of immune responses
###end article-title 78
###begin article-title 79
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
###end article-title 79
###begin article-title 80
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide
###end article-title 80
###begin article-title 81
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance
###end article-title 81
###begin article-title 82
Regulatory T cells in the control of immune pathology
###end article-title 82
###begin article-title 83
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production
###end article-title 83
###begin article-title 84
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state
###end article-title 84
###begin article-title 85
###xml 3 5 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
CD4+ regulatory T cells
###end article-title 85
###begin article-title 86
CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes
###end article-title 86
###begin article-title 87
TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression
###end article-title 87
###begin article-title 88
###xml 34 40 <span type="species:ncbi:10090">murine</span>
CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4
###end article-title 88
###begin article-title 89
CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells
###end article-title 89
###begin article-title 90
Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease
###end article-title 90
###begin article-title 91
CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells
###end article-title 91
###begin article-title 92
###xml 137 152 <span type="species:ncbi:10090">transgenic mice</span>
Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice
###end article-title 92
###begin article-title 93
Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis
###end article-title 93
###begin article-title 94
Immunopathogenesis of collagen arthritis
###end article-title 94
###begin article-title 95
Influence of CD4 or CD8 deficiency on collagen-induced arthritis
###end article-title 95
###begin article-title 96
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
###end article-title 96
###begin article-title 97
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice
###end article-title 97
###begin article-title 98
###xml 53 57 <span type="species:ncbi:10090">mice</span>
High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors
###end article-title 98
###begin article-title 99
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Enhanced autoimmune arthritis in IFN-gamma receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells
###end article-title 99
###begin article-title 100
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis
###end article-title 100
###begin article-title 101
###xml 34 38 <span type="species:ncbi:10090">mice</span>
IFNgamma deficient C57BL/6 (H-2b) mice develop collagen induced arthritis with predominant usage of T cell receptor Vbeta6 and Vbeta8 in arthritic joints
###end article-title 101
###begin article-title 102
###xml 157 162 <span type="species:ncbi:10090">mouse</span>
Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain
###end article-title 102
###begin article-title 103
CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis
###end article-title 103
###begin article-title 104
###xml 19 23 <span type="species:ncbi:10090">mice</span>
Immune response in mice that lack the interferon-gamma receptor
###end article-title 104
###begin article-title 105
###xml 55 61 <span type="species:ncbi:10090">murine</span>
Identification of a monoclonal antibody specific for a murine T3 polypeptide
###end article-title 105
###begin article-title 106
An overview of real-time quantitative PCR: applications to quantify cytokine gene expression
###end article-title 106
###begin article-title 107
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Female sex hormones suppress development of collagen-induced arthritis in mice
###end article-title 107
###begin article-title 108
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Homologous type II collagen induces chronic and progressive arthritis in mice
###end article-title 108
###begin article-title 109
Modes of action of Freund's adjuvants in experimental models of autoimmune diseases
###end article-title 109
###begin article-title 110
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 52 54 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta
###end article-title 110
###begin article-title 111
###xml 57 58 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 62 64 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 99 105 <span type="species:ncbi:9606">humans</span>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
TGF-beta1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice
###end article-title 111
###begin article-title 112
Interferon-gamma: biology and role in pathogenesis
###end article-title 112
###begin article-title 113
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 31 34 <span type="species:ncbi:31658">CFA</span>
Mac-1+ myelopoiesis induced by CFA: a clue to the paradoxical effects of IFN-gamma in autoimmune disease models
###end article-title 113
###begin article-title 114
Interferon gamma enhances both in vitro and in vivo priming of CD4+ T cells for IL-4 production
###end article-title 114
###begin article-title 115
Induction of IL-10-producing CD4+CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen
###end article-title 115
###begin article-title 116
CD4+CD25+ immunoregulatory T cells may not be involved in controlling autoimmune arthritis
###end article-title 116
###begin article-title 117
Biology of the interleukin-2 receptor
###end article-title 117
###begin article-title 118
The interleukin 2 receptor. Functional consequences of its bimolecular structure
###end article-title 118
###begin article-title 119
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
###end article-title 119
###begin article-title 120
Frontline: neuropilin-1: a surface marker of regulatory T cells
###end article-title 120
###begin article-title 121
Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease
###end article-title 121
###begin article-title 122
Signaling through the JAK/STAT pathway, recent advances and future challenges
###end article-title 122
###begin article-title 123
RANTES and MIP-1alpha activate Stats in T cells
###end article-title 123
###begin article-title 124
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells
###end article-title 124
###begin article-title 125
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3
###end article-title 125
###begin article-title 126
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells
###end article-title 126
###begin title 127
Figures and Tables
###end title 127
###begin p 128
###xml 222 226 222 226 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 232 236 232 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 356 358 356 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N </italic>
###xml 396 398 396 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N </italic>
###xml 404 408 404 408 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 429 431 429 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 629 630 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 634 636 634 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 729 736 729 736 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b, c) </bold>
###xml 858 862 858 862 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 871 875 871 875 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 1223 1226 1223 1226 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d)</bold>
###xml 1379 1381 1379 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1402 1403 1402 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 1447 1454 1447 1454 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e, f) </bold>
###xml 1595 1599 1595 1599 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 1636 1639 1636 1639 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f)</bold>
###xml 1641 1645 1641 1645 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 1976 1978 1976 1978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2045 2046 2045 2046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 387 390 <span type="species:ncbi:10116">rat</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 843 847 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
###xml 1023 1027 <span type="species:ncbi:10090">mice</span>
###xml 1265 1269 <span type="species:ncbi:10090">mice</span>
###xml 1373 1377 <span type="species:ncbi:10090">mice</span>
###xml 1566 1571 <span type="species:ncbi:10090">mouse</span>
###xml 1605 1610 <span type="species:ncbi:10090">mouse</span>
###xml 1720 1725 <span type="species:ncbi:10090">mouse</span>
###xml 2026 2030 <span type="species:ncbi:10090">mice</span>
Wild-type mice treated with anti-CD25 antibodies develop a more severe form of arthritis. In three experiments, wild-type DBA/1 mice were immunised on day 0 with collagen type II in complete Freund's adjuvant. From day 11 (c) or 13 (b) after immunisation onwards, mice were treated every second day with 0.25 mg of depleting anti-CD25 monoclonal antibody (N = 7) or with 0.25 mg control rat IgG (N = 7). (a) Depletion of the CD25+ cell population was checked in the blood twice a week by flow-cytometric analysis with anti-CD4 and anti-CD25 antibodies. A representative staining pattern on day 27 is shown. The percentages of CD4+CD25+ cells in control-treated mice (left plot) and anti-CD25-treated mice (right plot) are shown. (b, c) Cumulative incidence of arthritis (and mean day of disease onset) and the mean limb score of the arthritic mice in female (b) and male (c) wild-type mice treated with anti-CD25 or control IgG are shown (the maximum score per limb is 4). Error bars indicate SEM. The data from the female mice are representative of two independent experiments. The data of the three experiments were pooled and the percentage of limbs with each limb score on days 27 and 40 after immunisation is shown in (d). The mean limb score of the arthritic mice in the two groups is also indicated for the two time points and is significantly higher in the treated mice (P < 0.05; Mann-Whitney U-test) than in those receiving control IgG. (e, f) Representative pictures of the most severe case of collagen-induced arthritis on day 25 after immunisation of a mouse treated with anti-CD25 (e) and a mouse treated with control IgG (f). (g) Haematoxylin-stained paraffin section of the joint of an anti-CD25-treated mouse on day 42 after immunisation. Hyperplasia and infiltration of immunocompetent cells in the synovium (s) and pannus formation (p) that penetrates into the bone (b) can be seen. Note the presence of osteoclast-like multinucleated giant cells (arrow). *P < 0.05 for comparison with control IgG1-treated mice (Mann-Whitney U-test).
###end p 128
###begin p 129
###xml 60 61 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 65 67 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 68 72 64 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 92 96 88 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 117 121 113 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
###xml 642 647 <span type="species:ncbi:10090">mouse</span>
###xml 690 694 <span type="species:ncbi:10090">mice</span>
IFN-gamma is not required to establish normal numbers of CD4+CD25+ Treg cells. Thymus cells (a) and lymph node cells (b) were isolated from IFN-gammaR KO and wild-type DBA/1 mice, either naive (upper row) or having been immunised 21 days previously with collagen type II in complete Freund's adjuvant (collagen-induced arthritis (CIA), lower row). Cells were stained with anti-CD25-FITC, phycoerythrin-conjugated anti-CD4 and propidium iodide. Dead cells were excluded by gating on propidium iodide-negative cells. The percentages of cells in each quadrant are indicated. Each plot represents a staining pattern of cells from a single female mouse. Identical profiles were observed in male mice. The staining pattern is representative of data obtained in three experiments (Table 1).
###end p 129
###begin p 130
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 39 41 39 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 104 111 100 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a, b) </bold>
###xml 114 115 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 119 121 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 242 246 234 238 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 260 264 252 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 279 281 271 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 514 516 502 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 756 757 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 761 763 749 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 798 802 786 790 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 836 837 824 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 841 843 829 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 844 848 832 836 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 988 990 972 974 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1110 1111 1094 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1115 1117 1099 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1185 1187 1169 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 1422 1423 1403 1404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1427 1429 1408 1410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1465 1466 1446 1447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1470 1472 1451 1453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1525 1527 1506 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1633 1634 1614 1615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 869 873 <span type="species:ncbi:10090">mice</span>
###xml 970 974 <span type="species:ncbi:10090">mice</span>
###xml 1446 1450 <span type="species:ncbi:10090">mice</span>
###xml 1493 1497 <span type="species:ncbi:10090">mice</span>
###xml 1614 1618 <span type="species:ncbi:10090">mice</span>
Phenotypic characterisation of CD4+CD25+ T cells from immunised IFN-gammaR KO and wild-type DBA/1 mice. (a, b) CD4+CD25+ T cells isolated from IFN-gammaR KO and wild-type mice show a similar expression pattern of activation markers, in naive (a) and immunised (b) conditions. CD4+ T cells were purified from the lymph node cells of eight IFN-gammaR KO and wild-type DBA/1 mice, either naive or having been immunised 21 days previously with collagen type II in complete Freund's adjuvant (purity more than 99%). CD4+ T cells were stained for CD25 in combination with CD69, CD62L, CD44 or cytolytic T lymphocyte-associated antigen-4 (CTLA-4). Dead cells were excluded by gating on propidium iodide-negative cells. The numbers represent the percentages of CD4+CD25+ cells within the indicated marker. (c) Decreased Foxp3 mRNA levels in CD4+CD25+ Treg cells from immunised mice. Lymph node cells were isolated from eight naive or immunised IFN-gammaR KO and wild-type DBA/1 mice. Purified CD4+ T cells were stained with anti-CD25-FITC and phycoerythrin-conjugated anti-CD4, and sorted. The purity of the sorted CD4+CD25+ population was more than 97%. cDNA samples were prepared from 2 x 105 cells of each population and were subjected to real-time quantitative PCR analyses. The relative quantity of Foxp3 in each sample was normalised to the quantity of beta-actin. Error bars indicate standard error of the means of two (CD4+CD24+ cells from naive mice) or three (CD4+CD25+ cells from immunised mice) independent experiments. *P < 0.05 for comparison with Foxp3 expression of cells isolated from immunised wild-type mice (Mann-Whitney U-test).
###end p 130
###begin p 131
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 32 34 32 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 109 116 105 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a, b) </bold>
###xml 117 121 113 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 129 133 125 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 216 220 212 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 385 388 373 376 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 447 448 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 452 454 440 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 455 459 443 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 472 473 460 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 567 568 555 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 572 574 560 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 575 579 563 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 656 660 644 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 701 705 689 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 748 752 736 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 784 788 772 776 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 798 799 786 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 803 804 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 834 835 822 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 839 841 827 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 842 846 830 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 913 917 901 905 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 921 924 909 912 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 977 981 965 969 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 1074 1078 1062 1066 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 1082 1085 1070 1073 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 1009 1013 <span type="species:ncbi:10090">mice</span>
###xml 1035 1039 <span type="species:ncbi:10090">mice</span>
Suppressive capacity of CD4+CD25+ cells is decreased more in immunized IFN-gammaR KO than in wild-type mice. (a, b) Treg cells, Teff cells and accessory cells (ACs) were isolated from lymph nodes and spleen of naive (a) IFN-gammaR KO and wild-type DBA/1 mice or from IFN-gammaR KO and wild-type DBA/1 mice 21 days after immunisation with collagen type II in complete Freund's adjuvant (b). In each case, a group of seven to nine mice was used. CD4+CD25- Teff cells (5 x 104) were incubated with anti-CD3 antibody in the presence of ACs and the indicated number of CD4+CD25+ Treg cells. The percentage inhibition (100 x (Radioactivity in condition without Treg cells - Radioactivity in condition with Treg cells)/Radioactivity in condition without Treg cells) of the proliferation of Teff cells (CD4+CD25-) by increasing numbers of CD4+CD25+ Treg cells is shown. Two and seven independent experiments are shown in (a) and (b), respectively. Each result is the mean of two cups. (c) The means of the two (naive mice) or seven (immunised mice) independent experiments shown in (a) and (b). Error bars indicate SEM.
###end p 131
###begin p 132
###xml 88 92 84 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 103 107 99 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 115 119 111 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 364 366 356 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 369 370 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 374 376 366 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 377 381 369 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 479 480 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 484 486 476 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 487 491 479 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 549 553 541 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff </sub>
###xml 563 564 555 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 568 569 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 599 600 591 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 604 606 596 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 607 611 599 603 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
Accessory cells (ACs) of immunised IFN-gammaR KO mice are required for their defective Treg activity. Treg cells, Teff cells and ACs were isolated from lymph nodes and spleen of IFN-gammaR KO and wild-type DBA/1 mice 21 days after immunisation with collagen type II in complete Freund's adjuvant. Mixing experiments were performed as indicated. In each set, 5 x 104 CD4+CD25- Teff cells were incubated with anti-CD3 antibody in the presence of ACs and the indicated number of CD4+CD25+ Treg cells. The percentage inhibition of the proliferation of Teff cells (CD4+CD25-) by increasing numbers of CD4+CD25+ Treg cells is shown. The results are representative of two independent experiments.
###end p 132
###begin p 133
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
Proportion of regulatory T cells to the total CD4+ T cell population in lymphoid organs of naive and immunised IFN-gamma receptor knock-out and wild-type (WT) DBA/1 mice
###end p 133
###begin p 134
###xml 416 417 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 421 423 413 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 439 441 431 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 499 501 491 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N </italic>
###xml 598 600 590 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N </italic>
###xml 792 794 780 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 815 816 803 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 549 553 <span type="species:ncbi:10090">mice</span>
###xml 675 679 <span type="species:ncbi:10090">mice</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
Cells were obtained from thymuses, spleens or lymph nodes of IFN-gamma receptor knock-out (IFN-gammaR KO) and wild-type DBA/1 mice. In experiments 4 to 6, mice were immunised with collagen type II in complete Freund's adjuvant on day 0, and cells were obtained on day 21 (collagen-induced arthritis; CIA). Cells were stained with anti-CD25-FITC and phycoerythrin-conjugated anti-CD4 antibodies. The proportion of CD4+CD25+ in the total CD4+ T cell population is shown. In experiments 1, 2, 4 and 5, N (number in parentheses) indicates the number of mice in each experiment; in experiments 3 and 6, N represents the number of experiments, each consisting of groups of 5 to 10 mice, from which samples were pooled for analysis. *Significant difference between IFN-gammaR KO and wild-type mice (P < 0.05; Mann-Whitney U-test).
###end p 134

